BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26918701)

  • 1. Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer (†).
    Hvolris MH; Piper TB; Hammer E; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Christensen IJ; Brünner N; Johansen JS; Davis GJ; Dowell BL; Nielsen HJ
    Scand J Gastroenterol; 2016 Jul; 51(7):860-5. PubMed ID: 26918701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological cancer-associated protein biomarker levels at bowel endoscopy: Increased risk of subsequent primary malignancy.
    Piper TB; Nielsen HJ; Christensen IJ
    Tumour Biol; 2022; 44(1):1-16. PubMed ID: 35180141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?
    Piper TB; Jørgensen LN; Olsen J; Nielsen KT; Davis G; Johansen JS; Jarle Christensen I; Nielsen HJ
    Acta Oncol; 2019; 58(sup1):S42-S48. PubMed ID: 30523734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
    Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
    Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies.
    Kring TS; Piper TB; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Davis G; Dowell B; Johansen JS; Christensen IJ; Brünner N; Nielsen HJ
    Biomark Cancer; 2015; 7():57-61. PubMed ID: 26526637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
    Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
    Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
    Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
    Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
    Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
    PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers.
    Wilhelmsen M; Christensen IJ; Rasmussen L; Jørgensen LN; Madsen MR; Vilandt J; Hillig T; Klaerke M; Nielsen KT; Laurberg S; Brünner N; Gawel S; Yang X; Davis G; Heijboer A; Martens F; Nielsen HJ
    Int J Cancer; 2017 Mar; 140(6):1436-1446. PubMed ID: 27935033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures.
    Lech Pedersen N; Mertz Petersen M; Ladd JJ; Lampe PD; Bresalier RS; Davis GJ; Demuth C; Jensen SØ; Andersen CL; Ferm L; Christensen IJ; Nielsen HJ
    Clin Chim Acta; 2020 Aug; 507():39-53. PubMed ID: 32272156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
    Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
    Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
    Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
    Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
    Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
    Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum markers in early-stage and locally advanced melanoma.
    Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
    Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
    Iemura K; Moriya Y
    Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of determining tumor markers in patients with signs and symptoms of cancer.
    Trapé J; Sala M; Franquesa F; Ordeig JM; Soler-Bel JM; Bustamante E; Pérez R; Aligué J; Montesinos J; Arnau A; Ordeig-Villanueva R
    Clin Chem Lab Med; 2015 Feb; 53(3):485-91. PubMed ID: 25274947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.
    Wang YR; Yan JX; Wang LN
    J Cancer Res Ther; 2014 Dec; 10 Suppl():307-9. PubMed ID: 25693941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.